Validation of 24-Hour Posaconazole and Voriconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Application of Epidemiological Cutoff Values to Results from a Global Candida Antifungal Surveillance Program
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
We performed 24- and 48-h MIC determinations of posaconazole and voriconazole against more than 16,000 clinical isolates of Candida species. By using the 24- and 48-h epidemiological cutoff values (ECVs), the categorical agreement between the 24-h and reference 48-h broth microdilution results ranged from 97.1% ( C. parapsilosis and voriconazole) to 99.8% ( C. krusei and voriconazole), with 0.0 to 2.9% very major discrepancies (VMD). The essential agreement (within 2 log 2 dilutions) between the 24- and 48-h results was 99.6% for both posaconazole and voriconazole. The MIC results obtained for both posaconazole and voriconazole after only 24 h of incubation may be used to determine the susceptibilities of Candida spp. to these important antifungal agents. The applications of ECVs to this large collection of Candida isolates suggests the potential to develop 24-h species-specific clinical breakpoints for both posaconazole and voriconazole.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“The choice of antifungal therapy may be optimized by the use of routine onsite antifungal susceptibility testing (4, 5, 8, 13, 16, 18, 23, 27, 37).”
MethodMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171 · cited 2×
“Given that a shorter incubation period for antifungal susceptibility testing would avoid the potentially confounding effect of trailing growth on 48-h triazole MICs (3, 30, 35, 36), is more efficient and practical for use in the clinical laboratory (11, 30), and would provide useful information to clinicians sooner ra…”
BackgroundMethodSabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., & McNicholas, P. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00163-06 · Cited by 491 · cited 1×
“The MIC results for each agent were typical of those for each species of Candida (25, 31, 38).”
BackgroundHas antifungal susceptibility testing come of age
Rex, J. H., & Pfaller, M. A. (2002) · Clinical Infectious Diseases · doi:10.1086/342384 · Cited by 361 · cited 1×
“The choice of antifungal therapy may be optimized by the use of routine onsite antifungal susceptibility testing (4, 5, 8, 13, 16, 18, 23, 27, 37).”
MethodSelf-citationPfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314 · cited 2×
“The validation of 24-h MIC determinations and the establishment of new 24-h clinical breakpoints (CBPs) has been accomplished for the in vitro testing of fluconazole (32); however, progress has been lacking in this area for the newer triazoles, namely, posaconazole and voriconazole.”
BackgroundMethodSelf-citationPfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258 · cited 2×
“Categorical agreement (CA) between 24- and 48-h readings was assessed for voriconazole using the 48-h CBPs established by the CLSI (7, 29), demonstrating an acceptable overall CA of”
BackgroundMethodSelf-citationParkins, M. D., Sabuda, D. M., Elsayed, S., & Laupland, K. B. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm212 · Cited by 229
Treatment-related risk factors for hospital mortality in Candida bloodstream infections
Labelle, A. J., Micek, S. T., Roubinian, N., & Kollef, M. H. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31818b3477 · Cited by 181 · cited 1×
“There now are several lines of evidence that indicate that early and appropriate (correct dose and susceptible organism) antifungal therapy has a positive effect on outcomes and resource utilization for patients with candidemia (2, 14, 15, 19, 22, 24, 28, 39).”
BackgroundRex, J. H., Nelson, P. W., Paetznick, V. L., Lozano-Chiu, M., Espinel-Ingroff, A., & Anaissie, E. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.1.129 · Cited by 167 · cited 2×
“Given that a shorter incubation period for antifungal susceptibility testing would avoid the potentially confounding effect of trailing growth on 48-h triazole MICs (3, 30, 35, 36), is more efficient and practical for use in the clinical laboratory (11, 30), and would provide useful information to clinicians sooner ra…”
Method
Cited by
Chowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577
Kathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532
Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
Self-citationMultidrug-resistant endemic clonal strain of Candida auris in India
Chowdhary, A., Anil Kumar, V., Sharma, C., Prakash, A., Agarwal, K., Babu, R., Dinesh, K. R., Karim, S., Singh, S. K., Hagen, F., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2027-1 · Cited by 373
“[11, 12].”
Lockhart, S. R., Iqbal, N., Cleveland, A. A., Farley, M. M., Harrison, L. H., Bolden, C. B., Baughman, W., Stein, B., Hollick, R., Park, B. J., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01283-12 · Cited by 299
Arendrup, M. C., Prakash, A., Meletiadis, J., Sharma, C., & Chowdhary, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00485-17 · Cited by 270
Emerging multidrug-resistant Candida species
Colombo, A. L., Júnior, J. N. D. A., & Guinea, J. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000411 · Cited by 177
Pfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130
Self-citationIdentification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry
Aslani, N., Janbabaei, G., Abastabar, M., Meis, J. F., Babaeian, M., Khodavaisy, S., Boekhout, T., & Badali, H. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-017-2916-5 · Cited by 114
Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species
Fothergill, A. W., Sutton, D. A., McCarthy, D. I., & Wiederhold, N. P. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03044-13 · Cited by 96
Shokohi, T., Aslani, N., Ahangarkani, F., Meyabadi, M. F., Hagen, F., Meis, J. F., Boekhout, T., Kolecka, A., & Badali, H. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2017.12.069 · Cited by 11
Metadata
- Authors
- Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2011-04
- Volume
- 49
- Issue
- 4
- Pages
- 1274-1279
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2025563268
- Cited by
- 34
- References
- 14
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.